{
  "report_rows": [
    {
      "kpi": "Q2 Total Revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$2.460B vs. cons $2.456B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 Non-GAAP Diluted EPS",
      "prediction": "IN-LINE",
      "answer": "pred ~$2.90 vs. cons $2.876",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 LEQEMBI Revenue",
      "prediction": "BEAT",
      "answer": "pred ~$180M vs. cons $177.8M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 Total Revenue, Apellis-inclusive",
      "prediction": "UNCHANGED",
      "answer": "guide ~$9.95B-$10.10B vs. cons $10.033B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 Non-GAAP Diluted EPS, Apellis-inclusive",
      "prediction": "UNCHANGED",
      "answer": "guide ~$12.25-$13.00 vs. cons $12.599",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 commercial commentary",
      "prediction": "UNCHANGED",
      "answer": "reiterate MS pressure and launch-product/Apellis growth bridge vs. UNVERIFIED consensus",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -1.5,
  "day1_confidence": "LOW",
  "day5_residual_pct": -2.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 modest estimate pressure from an in-line package",
  "day5_confidence": "LOW"
}